Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR – Get Free Report) have received a consensus rating of “Hold” from the five brokerages that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $7.30.
A number of research analysts recently commented on ESPR shares. Needham & Company LLC reiterated a “buy” rating and issued a $6.00 price objective on shares of Esperion Therapeutics in a report on Friday, December 13th. The Goldman Sachs Group started coverage on shares of Esperion Therapeutics in a research report on Wednesday, December 18th. They set a “neutral” rating and a $4.00 price objective for the company. HC Wainwright reiterated a “buy” rating on shares of Esperion Therapeutics in a report on Friday, January 10th. StockNews.com lowered shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Finally, Cantor Fitzgerald assumed coverage on shares of Esperion Therapeutics in a report on Tuesday, December 17th. They issued an “overweight” rating and a $8.00 price objective for the company.
View Our Latest Stock Analysis on Esperion Therapeutics
Esperion Therapeutics Price Performance
Hedge Funds Weigh In On Esperion Therapeutics
Several hedge funds and other institutional investors have recently made changes to their positions in ESPR. Bank of New York Mellon Corp grew its stake in shares of Esperion Therapeutics by 3,278.3% during the second quarter. Bank of New York Mellon Corp now owns 572,323 shares of the biopharmaceutical company’s stock worth $1,271,000 after purchasing an additional 555,382 shares in the last quarter. Rhumbline Advisers increased its holdings in shares of Esperion Therapeutics by 6,560.6% in the 2nd quarter. Rhumbline Advisers now owns 252,038 shares of the biopharmaceutical company’s stock valued at $560,000 after acquiring an additional 248,254 shares during the last quarter. National Bank of Canada FI raised its position in shares of Esperion Therapeutics by 115.9% during the 2nd quarter. National Bank of Canada FI now owns 19,050 shares of the biopharmaceutical company’s stock worth $44,000 after acquiring an additional 10,225 shares in the last quarter. American Century Companies Inc. purchased a new stake in Esperion Therapeutics during the second quarter worth approximately $50,000. Finally, BOKF NA acquired a new position in Esperion Therapeutics in the second quarter valued at approximately $26,000. Hedge funds and other institutional investors own 47.39% of the company’s stock.
About Esperion Therapeutics
Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.
Recommended Stories
- Five stocks we like better than Esperion Therapeutics
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- The Fed Is More Likely to Hike Than Cut Rates in 2025
- Quiet Period Expirations Explained
- Investors Navigate Uncertainty by Seeking Refuge in Gold and Oil
- How to Use the MarketBeat Stock Screener
- Archer Aviation Shares Slide, Now Bargain Priced for 2025
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.